CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Lenalidomide +3 moredrug
Likely dose
Bortezomib 1.3 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724568
NCT00724568Phase 2Completed
CompareCT.gov

A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

University of Michigan Rogel Cancer Center·interventional·Posted Jul 29, 2008·Updated Jun 2, 2017

In Brief

A Phase 2 clinical trial evaluating Lenalidomide, Bortezomib, and 2 other interventions for Multiple Myeloma. Completed, enrolled 74 participants across 6 sites in 2 countries.

Detailed Summary

This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2009
Study CompletionSep 3, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.9 years ago

Interventions

Lenalidomidedrug

Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.

Bortezomibdrug

Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11

Dexamethasonedrug

Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.

Doxildrug

Patients will be treated with Doxil on day 4.